

**Statement of need**

The Ethics of Cell Therapy Conference will explore the interface of cell therapy treatments with the ethical framework in which they exist. Presentations will be made about the latest therapeutic innovations, followed by comment and discussion by our ethics experts, who will guide participants through the issues that should be considered with each kind of therapy described. These screening or intervention discussions will be succeeded by a review of the specific ethical considerations that attend decisions made by patients and their families, care givers, and the community at large.

The goal of this conference is to enable participants to: explain and discuss treatment alternatives to families of children with inborn errors of metabolism; present the difficulties of previous attempts in trials of gene therapy and compare them against similar interventions with cell therapy; become informed participants in the debate of mandatory versus voluntary screening at birth for inborn errors of metabolism; and give patients and their families referrals to certified and knowledgeable testing sources for detecting inborn errors of metabolism.

**Target audience**

Physicians specializing in internal medicine, pediatrics, obstetrics/gynecology, immunology, surgery, medical oncology, and cardiology.

**Learning objectives**

Following participation in this activity, participants should be able to:

1. Identify the consequences of late vs. early transplantation to correct inborn errors of metabolism and the consequences for the family of the affected patient.
2. Discuss three major issues, either pro or con, for pre-birth diagnosis for serious, correctable inherited genetic diseases raised by public newborn screening.
3. Describe two publicly funded initiatives in the United States that assist with transplantation programs.

**Credit designation**

The Duke University School of Medicine designates this educational activity for a maximum of **1.1 AMA PRA Category 1 Credit(s)<sup>TM</sup>**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**Accreditation**

The Duke University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Support acknowledgment**

This CME activity is supported by a clinical translational science award from the NIH.

**Faculty disclosure**

The Duke University School of Medicine adheres to ACCME Essential Areas, Standards, and Policies regarding industry support of continuing medical education. Disclosure of faculty and commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or any discussion of any off-label, experimental, or investigational uses of drugs or devices in their presentations.

**Disclaimer**

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

**Special needs statement**

The Duke University School of Medicine is committed to making its activities accessible to all individuals. If you are in need of an accommodation, please do not hesitate to call and/or submit a description of your needs in writing in order to receive service.

**Cancellation Policy**

A written notice of cancellation must be received by May 30, 2008. A \$25.00 cancellation fee will be assessed at that time; after that date, cancellation requests cannot be honored.

**Conference fee**

\$50.00 for physicians and other attendees  
There is no charge for residents and fellows.

**For conference information, visit:**

<http://www.dtmi.duke.edu/dtri/cell-therapies/>

**For conference registration, visit:**

<https://banquo.duhs.duke.edu/dtmi/cell.nsf/ethics>

**Activity Medical Director**

N. Rebecca Haley, M.D.  
Program Director  
Cell and Tissue Therapy Core - DTRI

**For more information, please contact:**

**Pam Riley**  
**Manager, Clinical Education & Events**  
Duke Clinical Research Institute  
Hock Plaza, Room 4035  
2424 Erwin Rd., Durham NC 27705  
[pam.riley@duke.edu](mailto:pam.riley@duke.edu)  
**919-668-5928, fax 919-668-7114**

## Speakers and topics

### Monday, June 16

**Welcome; Introduction of the Ethicists and Purpose of the Conference - 8:30 AM**

**Overview of the Horizons of Cell Therapy - 8:45 AM**

Robert M. Califf, MD  
Duke University

**The History of Gene Transfer Research in Lieu of Cellular Therapy - 9:00 AM**

Robert Cook-Deegan, MD  
Duke University

### Section I

---

**Cord Blood Transplantation in Infant Inherited Metabolic Disorders - 9:30 AM**

Joanne Kurtzberg, MD  
Duke University

**Thymus Transplants for DiGeorge Syndrome - 9:50 AM**

M. Louise Markert, MD, PhD  
Duke University

**ALDH<sup>br</sup> Cells in Liver Repair - 10:10 AM**

Jan Nolte, PhD  
University of California, Davis

**Break - 10:30 AM**

**Parent Advocate - 10:45 AM**

Bob Evanosky  
Chicago, IL

**Ethical Issues - 11:15 AM**

Hank Greely, JD  
Stanford University

**Lunch - 12:00 PM**

**Section II—Cord Blood Banking and Other Programs to Support Cell Transplantation**

---

**Cord Blood Banking - 1:30 PM**

Liana Harvath, PhD  
Rockville, MD

**Other Programs to Support Cell Transplants - 2:00 PM**

James Burdick, MD  
HRSA

**Ethical Issues: Public vs. Private Support of Programs for Transplant Discussion and Panel - 2:30 PM**

Introduction of Issues: Joanne Kurtzberg, MD  
Panel Moderator: Hank Greely, JD

**Break - 3:00 PM**

*Sponsored by the Duke University School of Medicine*

### Section III—Newborn Screening: The New York Experience

---

**Krabbe Newborn Screening: One Small Foot, One Giant Step - 3:20 PM**

Laura Helton, MD  
Joe Orsini, PhD  
Michele Caggana, ScD  
New York State

**Ethics Discussion: Discussion and Panel - 4:20 PM**

Marilyn Telen, MD  
Joanne Kurtzberg, MD  
Duke University  
Hank Greely, JD  
Stanford University

**Adjourn - 5:30 PM**

### Tuesday, June 17

### Section IV—Early Diagnosis and Prevention

---

**Preimplantation Genetic Diagnosis - 8:30 AM**

Mark Hughes, MD, PhD  
Genesis Genetics, Detroit, MI

**Fetal Transplantation in Grave Metabolic Disorders - 9:00 AM**

Joanne Kurtzberg, MD  
Duke University

**Ethics of Pre-Birth Diagnosis - 9:15 AM**

Anne Drapkin Lyerly, MD  
Duke University

**Break - 10:00 AM**

### Section V—Cell Therapies for Cancer

---

**Reduced Intensity Chemotherapy - 10:10 AM**

Thomas Shea, MD  
University of North Carolina at Chapel Hill

**The History of Cellular Vaccines - 10:30 AM**

Michael Morse, MD  
Duke University

**Adoptive Immunotherapy - 10:50 AM**

Carl June, MD  
University of Pennsylvania

**Transformed Cellular Therapies - 11:10 AM**

Catherine Bollard, PhD  
Baylor University

**Ethical Issues in Cancer Treatments - 11:30 AM**

Robert Cook-Deegan, MD  
Duke University

*Opportunities for Q&A will be provided at the conclusion of each section.*

**Adjourn - 1:00 PM**